We are live on ! Find out more
EFM

E Fund Management Portfolio holdings

AUM $3.37B
This Fund
S&P 500
This Quarter Est. Return
+0.28%
1 Year Est. Return
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$1.22B
AUM Growth
+$983M
Cap. Flow
+$1.08B
Cap. Flow %
88.66%
Top 10 Hldgs %
61.71%
Holding
251
New
250
Increased
1
Reduced
Closed

Top Buys

Rank Stock Value
1
BABA icon
Alibaba
BABA
+$110M
2
JD icon
JD.com
JD
+$85.6M
3
TAL icon
TAL Education Group
TAL
+$81M
4
PDD icon
Pinduoduo
PDD
+$74.8M
5
BIDU icon
Baidu
BIDU
+$64.6M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 45.92%
2 Technology 14.46%
3 Communication Services 12.8%
4 Consumer Staples 7.42%
5 Healthcare 5.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IRWD icon
226
Ironwood Pharmaceuticals
IRWD
$652M
$137K 0.01%
+12,254
New +$129K
OPK icon
227
Opko Health
OPK
$936M
$134K 0.01%
+31,230
New +$149K
VBIV
228
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$134K 0.01%
+1,431
New +$145K
AKBA icon
229
Akebia Therapeutics
AKBA
$341M
$130K 0.01%
+38,410
New +$138K
FOLD
230
DELISTED
Amicus Therapeutics
FOLD
$127K 0.01%
+12,862
New +$199K
IMGN
231
DELISTED
Immunogen Inc
IMGN
$127K 0.01%
+15,645
New +$128K
VXRT
232
DELISTED
Vaxart
VXRT
$124K 0.01%
+20,573
New +$158K
INO icon
233
Inovio Pharmaceuticals
INO
$80.4M
$123K 0.01%
+1,100
New +$145K
DTIL icon
234
Precision BioSciences
DTIL
$188M
$122K 0.01%
+392
New +$137K
KPTI icon
235
Karyopharm Therapeutics
KPTI
$162M
$118K 0.01%
+751
New +$158K
BCRX icon
236
BioCryst Pharmaceuticals
BCRX
$2.47B
$112K 0.01%
+10,970
New +$113K
SRNE
237
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$112K 0.01%
+13,528
New +$143K
KDMN
238
DELISTED
Kadmon Holdings, Inc.
KDMN
$108K 0.01%
+27,713
New +$127K
PGEN icon
239
Precigen
PGEN
$1.96B
$107K 0.01%
+15,475
New +$131K
ATNX
240
DELISTED
Athenex, Inc. Common Stock
ATNX
$107K 0.01%
+1,249
New +$239K
ADVM
241
DELISTED
Adverum Biotechnologies
ADVM
$100K 0.01%
+1,014
New +$122K
EPZM
242
DELISTED
Epizyme, Inc
EPZM
$99K 0.01%
+11,351
New +$117K
OCGN icon
243
Ocugen
OCGN
$433M
$94K 0.01%
+13,866
New +$92.2K
VKTX icon
244
Viking Therapeutics
VKTX
$4.14B
$92K 0.01%
+14,481
New +$102K
RIGL icon
245
Rigel Pharmaceuticals
RIGL
$708M
$89K 0.01%
+2,603
New +$103K
CPRX
246
DELISTED
Catalyst Pharmaceutical
CPRX
$84K 0.01%
+18,138
New +$72.1K
TCRT icon
247
Alaunos Therapeutics
TCRT
$4.64M
$81K 0.01%
+150
New +$93.4K
SPPI
248
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$79K 0.01%
+24,314
New +$87.2K
AGEN
249
Agenus
AGEN
$257M
$74K 0.01%
+1,381
New +$99.8K
GERN icon
250
Geron
GERN
$949M
$51K ﹤0.01%
+32,199
New +$57.5K

Similar funds

E Fund Management's Q1 2021 Portfolio in Review

As of Q1 2021, E Fund Management held 251 positions worth $1.22B, up 421% from $233M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

E Fund Management deployed $1.08B of net new capital in Q1 2021, opening 250 new positions and adding to 1 existing holding. Its largest new stake was JD.com: 934,020 shares worth $78.8M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 46% of assets, down from 100% a quarter earlier, followed by Technology and Communication Services.

  • E Fund Management's largest Q1 2021 buy was JD.com: 934,020 shares worth $78.8M.
  • E Fund Management added most to Alibaba in Q1 2021, an estimated $110M increase.
  • E Fund Management's ten largest holdings make up 62% of its $1.22B portfolio in Q1 2021.
  • E Fund Management opened 250 new positions and closed 0 in Q1 2021.
  • E Fund Management's portfolio value rose 421% quarter-over-quarter to $1.22B.

Based on E Fund Management's 13F filing for Q1 2021, filed 12 May 2021.